Answers are grounded in this paper and cite their sources.
A novel compound, KFM 19, is introduced, which turned out to be a selective adenosine A1-antagonist with good bioavailability. Its pharmacological profile suggests a high therapeutic potential for dementia and related cognitive deficits.
No takes yet. Share an insight, caveat, or question.
Schingnitz et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: